AI Summary
We reviewed 4 live results for besremi and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Haematology.
We reviewed 4 live results for besremi and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Haematology.
Source: PharmaEssentia Singapore Pte. Ltd.
Description
Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA).
Best for
patients with Polycythemia Vera, long-acting interferon therapy, specialized haematology care and prescription biological treatments
Rating
Source: PharmaEssentia
Description
Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option.
Best for
Polycythemia Vera patients, long-acting interferon therapy, newly registered HSA treatments and hematology patients
Rating
Source: Precision Healthcare (Singapore)
Description
A specialty therapeutic offering of Besremi (ropeginterferon alfa-2b) for patients requiring treatment for Polycythemia Vera. This product is listed in the haematology catalog for procurement within Singapore, providing a critical option for clinicians and patients managing blood-related disorders with modern biological therapies.
Best for
direct medical supply sourcing, healthcare providers, haematology patients and specialized drug procurement
Rating
| Compare | Besremi (ropeginterferon alfa-2b) | Besremi | Besremi 500mcg/mL Prefilled Syringe |
|---|---|---|---|
| Source | PharmaEssentia Singapore Pte. Ltd. | PharmaEssentia | Precision Healthcare (Singapore) |
| Description | Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA). | Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option. | A specialty therapeutic offering of Besremi (ropeginterferon alfa-2b) for patients requiring treatment for Polycythemia Vera. This product is listed in the haematology catalog for procurement within Singapore, providing a critical option for clinicians and patients managing blood-related disorders with modern biological therapies. |
| Best for | patients with Polycythemia Vera, long-acting interferon therapy, specialized haematology care and prescription biological treatments | Polycythemia Vera patients, long-acting interferon therapy, newly registered HSA treatments and hematology patients | direct medical supply sourcing, healthcare providers, haematology patients and specialized drug procurement |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Besremi (ropeginterferon alfa-2b) from PharmaEssentia Singapore Pte. Ltd.."
I picked this because As the official local subsidiary of the manufacturer, this entity provides the primary source-backed pharmaceutical supply and regulatory oversight for Besremi in Singapore.